Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Eye Care

Journal Scan / Research · December 07, 2016

Ripasudil May Be a Beneficial Addition to Maximum Medical Therapy in Glaucoma

Journal of Glaucoma

 

Additional Info

Journal of Glaucoma
Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy
J. Glaucoma 2016 Sep 21;[EPub Ahead of Print], H Inazaki, S Kobayashi, Y Anzai, H Satoh, S Sato, M Inoue, S Yamane, K Kadonosono

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading